- Home
- SMTK vs SPRB Comparison
SMTK vs SPRB Comparison
Compare SMTK & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- SPRB
- Stock Information
- Founded
- SMTK 2009
- SPRB 2014
- Country
- SMTK United Kingdom
- SPRB United States
- Employees
- SMTK N/A
- SPRB N/A
- Industry
- SMTK
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- SMTK
- SPRB Health Care
- Exchange
- SMTK NYSE
- SPRB Nasdaq
- Market Cap
- SMTK 13.3M
- SPRB 15.7M
- IPO Year
- SMTK N/A
- SPRB 2020
- Fundamental
- Price
- SMTK $2.61
- SPRB $0.42
- Analyst Decision
- SMTK
- SPRB Hold
- Analyst Count
- SMTK 0
- SPRB 7
- Target Price
- SMTK N/A
- SPRB $2.17
- AVG Volume (30 Days)
- SMTK 14.6K
- SPRB 416.2K
- Earning Date
- SMTK 03-04-2025
- SPRB 03-12-2025
- Dividend Yield
- SMTK N/A
- SPRB N/A
- EPS Growth
- SMTK N/A
- SPRB N/A
- EPS
- SMTK N/A
- SPRB N/A
- Revenue
- SMTK $40,000.00
- SPRB $7,101,000.00
- Revenue This Year
- SMTK N/A
- SPRB N/A
- Revenue Next Year
- SMTK N/A
- SPRB N/A
- P/E Ratio
- SMTK N/A
- SPRB N/A
- Revenue Growth
- SMTK 471.43
- SPRB N/A
- 52 Week Low
- SMTK $2.01
- SPRB $0.34
- 52 Week High
- SMTK $13.00
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- SPRB 58.94
- Support Level
- SMTK N/A
- SPRB $0.38
- Resistance Level
- SMTK N/A
- SPRB $0.42
- Average True Range (ATR)
- SMTK 0.00
- SPRB 0.03
- MACD
- SMTK 0.00
- SPRB 0.00
- Stochastic Oscillator
- SMTK 0.00
- SPRB 69.77
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).